Recently, the spesolimab injection(trade name: 圣利卓/ Spevigo)of Boehringer Ingelheim International GmbH is approved for marketing through the priority review and approval procedure by NMPA in China. This product is intended for treatment of generalized pustular psoriasis (GPP) flares in adults.

　　Spesolimab is a humanised antagonistic monoclonal immunoglobulin G1 (IgG1) antibody which could bind with IL36R to prevent the subsequent activation of IL36R by cognate ligands (IL-36 α, β and γ), thus inhibiting the pro-inflammatory and pro-fibrotic pathways in inflammatory skin diseases. The marketing of this product provides a new treatment option for GPP patients.